HUNGARIAN EXPERIENCES WITH LEVODOPA/CARBIDOPA INTESTINAL GEL IN THE TREATMENT OF ADVANCED PARKINSON'S DISEASE

被引:0
|
作者
Nagy, Helga [1 ,2 ]
Takats, Annannaria [1 ]
Toth, Adrian [1 ]
Bereczki, Daniel [1 ]
Klivenyi, Peter [3 ]
Dezsi, Livia [3 ]
Dibo, Gyoergy [3 ]
Vecsei, Laszlo [3 ,4 ]
Kovacs, Norbert [5 ]
Aschermann, Zsuzsa [5 ]
Komoly, Samue, I [5 ]
Varannai, Lajos [6 ]
Zemlenyi, Gyoengyi [6 ]
Valikovics, Attila [6 ]
机构
[1] Semmelweis Egyet, Neurol Klin, H-1083 Budapest, Hungary
[2] Orszagos Orvosi Rehabil Int, Budapest, Hungary
[3] Szegedi Tudomonyegyetem, Neurol Klin, Szeged, Hungary
[4] MTA SZTE, Szeged, Hungary
[5] Pecsi Tudomanyegyetem, Neurol Klin, Pecs, Hungary
[6] Borsod Abauj Zemplen Megyei Korhoz, Neurol Osztoly, Miskolc, Hungary
来源
关键词
advanced Parkinson's disease; motor and non - motor fluctuations; disturbing dyskinesias; effectiveness of LCIG therapy; results in Hungary; DUODENAL LEVODOPA INFUSION; CONTINUOUS DOPAMINERGIC STIMULATION; CONTINUOUS DRUG-DELIVERY; INTRAJEJUNAL LEVODOPA; NONMOTOR SYMPTOMS; MOTOR; EFFICACY; MULTICENTER; SAFETY;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In the advanced Parkison's disease (PD) the late complications of levodopa therapy have to be considered: motor and/or non-motor fluctuations with or without disturbing dyskinesias. The non-motor fluctuations often influence the quality of life (QoL) in a much more negative way compared with the motor symptoms. In the treatment of advanced PD there are several device-aided methods - deep brain stimulation, apomorphine pump, levodopa/carbidopa intestinal gel (LCIG) - to improve the symptoms, the QoL, sometimes even in an individual, tailored custom form. The LCIG therapy was introduced in Hungary in 2011. Here we summarize the data of our patients: we have tested almost 60 patients and in 43 cases we have started this treatment. We analyze the duration of illness, levodopa therapy, motor and non-motor fluctuation of patients and present our experiences with the test phase and the chronic LCIG therapy via PEG/PEJ implantation. We paid attention to the surgery and device - depending side effects. Our experiences are similar to the international data. In patients selection "the right treatment, to the right patient, in the right time" is of importance.
引用
收藏
页码:385 / 389
页数:5
相关论文
共 50 条
  • [21] Levodopa/carbidopa intestinal gel (treatment in advanced Parkinson's disease: A long-term observational study
    Havrankova, P.
    Klempir, J.
    Fialova, M.
    Rezkova, A.
    Petrtyl, J.
    Capek, V.
    Ruzicka, E.
    Roth, J.
    Jech, R.
    MOVEMENT DISORDERS, 2016, 31 : S654 - S654
  • [22] Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease
    Valldeoriola, Francesc
    Jose Catalan, Maria
    Escamilla-Sevilla, Francisco
    Freire, Eric
    Olivares, Jesus
    Cubo, Esther
    Santos Garcia, Diego
    Calopa, Matilde
    Martinez-Martin, Pablo
    Carlos Parra, Juan
    Arroyo, Gloria
    Matias Arbelo, Jose
    NPJ PARKINSONS DISEASE, 2021, 7 (01)
  • [23] Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
    Antonini, Angelo
    Fung, Victor S. C.
    Boyd, James T.
    Slevin, John T.
    Hall, Coleen
    Chatamra, Krai
    Eaton, Susan
    Benesh, Janet A.
    MOVEMENT DISORDERS, 2016, 31 (04) : 530 - 537
  • [24] Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
    Francesc Valldeoriola
    María José Catalán
    Francisco Escamilla-Sevilla
    Eric Freire
    Jesús Olivares
    Esther Cubo
    Diego Santos García
    Matilde Calopa
    Pablo Martínez-Martín
    Juan Carlos Parra
    Gloria Arroyo
    José Matías Arbelo
    npj Parkinson's Disease, 7
  • [25] Titration of Levodopa-Carbidopa Intestinal Gel in US Patients with Advanced Parkinson's Disease
    Aldred, Jason
    Davis, Thomas
    Zamudio, Jorge
    Kukreja, Pavnit
    Bergmann, Lars
    Li, Mei
    Standaert, David
    MOVEMENT DISORDERS, 2018, 33 : S93 - S93
  • [26] Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease
    Jose Catalan, Maria
    Antonio Molina-Arjona, Jose
    Mir, Pablo
    Cubo, Esther
    Matias Arbelo, Jose
    Martinez-Martin, Pablo
    JOURNAL OF NEUROLOGY, 2018, 265 (06) : 1279 - 1287
  • [27] Levodopa/carbidopa intestinal gel for managing pain related to levodopa-induced dystonia in advanced Parkinson's disease
    Alborghetti, Marika
    Rinaldi, Domiziana
    Sforza, Michela
    Bianchini, Edoardo
    Ceriello, Francesco
    Pontieri, Francesco
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [28] Efficacy of levodopa-carbidopa intestinal gel compared to oral levodopa-carbidopa in advanced Parkinson's disease: Sensitivity and responder analyses
    Boyd, J. T.
    Fernandez, H. H.
    Slevin, J. T.
    Espay, A. J.
    Standaert, D. G.
    Pritchett, Y.
    Zhang, W.
    Chatamra, K.
    Widnell, K. L.
    Benesh, J.
    MOVEMENT DISORDERS, 2013, 28 : S143 - S143
  • [29] Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson's disease
    Szasz, J.
    Constantin, V.
    Orban-Kiss, K.
    Bataga, S.
    Bancu, L.
    Neagoe, R.
    Szederjesi, J.
    Ciorba, M.
    Mihaly, I.
    Kelemen, K.
    Szatmari, S.
    MOVEMENT DISORDERS, 2023, 38 : S628 - S628
  • [30] Sleep quality in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel infusion
    De Fabregues, O.
    Ferre, A.
    Romero, O.
    Dot, J.
    Abu-Suboh, M.
    Quintana, M.
    Armengol, J. R.
    Alvarez-Sabin, J.
    MOVEMENT DISORDERS, 2017, 32